triazoles has been researched along with Schizophrenia in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (14.81) | 18.7374 |
| 1990's | 3 (11.11) | 18.2507 |
| 2000's | 4 (14.81) | 29.6817 |
| 2010's | 15 (55.56) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Bilecki, W; Chmelova, M; Maćkowiak, M; Majcher-Maślanka, I; Wawrzczak-Bargieła, A | 1 |
| Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Suzuki, H | 1 |
| Harasawa, T; Kawai, T; Komatsu, H; Kurimoto, E; Maruyama, M; Nishiyama, K; Sakuma, K; Shimizu, Y; Shimojo, M; Suzuki, H; Suzuki, N | 1 |
| Boldry, MC; Brar, J; Brunzell, DH; Ford, L; Gannon, J; Herb, T; Karelitz, JL; Michael, V; Perkins, KA; Rassnick, S; Roy Chengappa, KN | 1 |
| Huang, M; Kwon, S; Meltzer, HY; Michael, E; Rajagopal, L | 1 |
| Maehara, S | 1 |
| Albasanz, JL; Barrachina, M; Blanch, M; Díaz-Sánchez, S; Ferrer, I; Martín, M; Monje, A; Pereira-Veiga, T; Planchat, LM; Villar-Menéndez, I | 1 |
| Aguirre, C; Albeniz, JM; Echaburu, SD; García, MG; Hernandez, R; Lertxundi, U; Ruiz, B | 1 |
| Egecioglu, E; Engel, JA; Jerlhag, E; Smith, RG; Svensson, L | 1 |
| Antoni, G; Bodén, R; Ekselius, L; Larsson, EM; Lubberink, M; Persson, J; Wall, A | 1 |
| Preskorn, SH | 1 |
| Ohta, H; Satow, A; Suzuki, G | 1 |
| Ball, MP; Barch, DM; Buchanan, RW; Csernansky, JG; Goff, DC; Gold, JM; Green, MF; Jarskog, LF; Javitt, DC; Keefe, RS; Kern, RS; Kimhy, D; Kraus, MS; Lieberman, JA; Marder, SR; McEvoy, JP; McMahon, RP; Mesholam-Gately, RI; Robinson, J; Seidman, LJ | 1 |
| Aota, M; Doihara, H; Harada, K; Matsuoka, N; Morita, M; Nakato, K; Ni, K; Saita, K; Sato, Y; Takahashi, S; Yamaji, T; Yamazaki, M; Yarimizu, J | 1 |
| Gil, C; Lipina, TV; Martinez, A; Palomo, V; Roder, JC | 1 |
| Anderson, R; Carlson, G; Gandal, MJ; Gur, RE; Jonak, G; Klook, K; Leitman, V; Liang, Y; Ortinski, PI; Pierce, RC; Siegel, SJ; Sisti, J; Thieu, T | 1 |
| Engin, E; Liu, J; Rudolph, U | 1 |
| Berk, M; Wynchank, D | 1 |
| Nawrot, M | 1 |
| Ferré, S; Fredholm, BB; Fuxe, K; Lillrank, SM; Lipska, BK; Weinberger, DR | 1 |
| Appelberg, B; Joffe, G; Rimón, R | 1 |
| Guitart, X; Sánchez-Arroyos, R | 1 |
| Andreu, F; Farré, AJ; Guitart, X; Ovalle, S; Zamanillo, D | 1 |
| Vinar, O | 1 |
| Udabe, RU | 1 |
| Ban, TA; Galvan, L; Kussin, D; Nair, NP | 1 |
| Amin, M; Ban, TA; Bronheim, LA; Galvan, L; Klingner, A; Lehmann, HE; Nair, NP; Vergara, L; Zoch, C | 1 |
4 review(s) available for triazoles and Schizophrenia
| Article | Year |
|---|---|
[Pharmacological characterization of metabotropic glutamate-receptor 1 antagonist for the treatment of schizophrenia].
Topics: Animals; Benzimidazoles; Drug Discovery; Humans; Isoindoles; Mice; Molecular Targeted Therapy; Naphthalenes; Protein Binding; Rats; Receptors, Metabotropic Glutamate; Schizophrenia; Thiazoles; Triazoles | 2013 |
α2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders.
Topics: Alcoholism; Animals; Anxiety; Central Nervous System Diseases; Chronic Pain; Cognition Disorders; Depression; GABA-A Receptor Agonists; Humans; Polymorphism, Genetic; Pyridazines; Receptors, GABA-A; Schizophrenia; Substance-Related Disorders; Triazoles | 2012 |
Disorders of motion and depth.
Topics: Alzheimer Disease; Amblyopia; Antidepressive Agents; Cerebral Veins; Cues; Depth Perception; Epilepsy; Humans; Mesencephalon; Motion Perception; Occipital Lobe; Perceptual Disorders; Piperazines; Schizophrenia; Sinus Thrombosis, Intracranial; Temporal Lobe; Triazoles; Vestibular Diseases; Williams Syndrome | 2003 |
Clinical experience with a new psychotropic drug, trazodone: a review of literature.
Topics: Amitriptyline; Antidepressive Agents; Anxiety; Chlordiazepoxide; Clinical Trials as Topic; Depression; Diazepam; Drug Tolerance; Humans; Imipramine; Piperazines; Pyridines; Schizophrenia; Tranquilizing Agents; Triazoles | 1973 |
6 trial(s) available for triazoles and Schizophrenia
| Article | Year |
|---|---|
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
Topics: Adolescent; Adult; Cognition; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; GABA Agonists; Humans; Male; Middle Aged; Neuropsychological Tests; Psychiatric Status Rating Scales; Pyridazines; Receptors, GABA-A; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Triazoles; Young Adult | 2011 |
Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
Topics: Acute Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male; Piperazines; Receptors, Serotonin, 5-HT2; Schizophrenia; Serotonin Antagonists; Substance-Related Disorders; Triazoles | 2003 |
Adjunctive nefazodone in neuroleptic-treated schizophrenic patients with predominantly negative symptoms: an open prospective pilot study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Serotonin Antagonists; Triazoles | 1999 |
Clinical experience with a new psychotropic drug, trazodone: a review of literature.
Topics: Amitriptyline; Antidepressive Agents; Anxiety; Chlordiazepoxide; Clinical Trials as Topic; Depression; Diazepam; Drug Tolerance; Humans; Imipramine; Piperazines; Pyridines; Schizophrenia; Tranquilizing Agents; Triazoles | 1973 |
Trazodone in the treatment of schizophrenias.
Topics: Antidepressive Agents; Chronic Disease; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Piperazines; Placebos; Psychiatric Status Rating Scales; Pyridines; Schizophrenia; Time Factors; Tranquilizing Agents; Triazoles | 1973 |
Differential effects of trazodone in depressed, schizophrenic and geriatric patients.
Topics: Adult; Antidepressive Agents; Clinical Trials as Topic; Dementia; Depression; Female; Humans; Male; Middle Aged; Neurocognitive Disorders; Piperazines; Psychiatric Status Rating Scales; Pyridines; Schizophrenia; Time Factors; Triazoles | 1974 |
18 other study(ies) available for triazoles and Schizophrenia
| Article | Year |
|---|---|
Inhibition of BET Proteins during Adolescence Affects Prefrontal Cortical Development: Relevance to Schizophrenia.
Topics: Adolescent; Adolescent Development; Animals; Azepines; Disease Models, Animal; Female; Gene Expression Regulation, Developmental; Humans; Long-Term Potentiation; Male; Methylazoxymethanol Acetate; Prefrontal Cortex; Proteomics; Rats; Recognition, Psychology; Schizophrenia; Sex Characteristics; Triazoles | 2021 |
Reduced insomnia following short-term administration of suvorexant during aripiprazole once-monthly treatment in a patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Azepines; Female; Humans; Schizophrenia; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles | 2017 |
FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia.
Topics: Animals; Antipsychotic Agents; Benzamides; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Nootropic Agents; Nucleus Accumbens; Organ Culture Techniques; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Rats, Wistar; Receptors, G-Protein-Coupled; Schizophrenia; Treatment Outcome; Triazoles | 2017 |
Initial Cross-Over Test of A Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers With Or Without Schizophrenia.
Topics: Adult; Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Nicotinic Agonists; Pyridines; Schizophrenia; Smoking; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Disorder; Treatment Outcome; Triazoles | 2018 |
TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABA
Topics: Animals; Cognitive Dysfunction; Dose-Response Relationship, Drug; GABA-A Receptor Agonists; Hallucinogens; Male; Mice; Mice, Inbred C57BL; Phencyclidine; Pyridazines; Reversal Learning; Schizophrenia; Triazoles | 2018 |
Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia.
Topics: Actins; Adenosine A1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cell Membrane; DNA Methylation; Female; Humans; Lewy Body Disease; Male; Middle Aged; Positron-Emission Tomography; Postmortem Changes; Psychiatric Status Rating Scales; Putamen; Receptor, Adenosine A2A; Schizophrenia; Triazines; Triazoles; Tritium; Xanthines | 2014 |
Possible interaction between letrozole and long-acting injectable zuclopenthixol.
Topics: Aged; Antineoplastic Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clopenthixol; Dibenzothiazepines; Drug Interactions; Female; Humans; Letrozole; Nitriles; Quetiapine Fumarate; Schizophrenia; Triazoles | 2015 |
Blockade of growth hormone secretagogue receptor 1A signaling by JMV 2959 attenuates the NMDAR antagonist, phencyclidine-induced impairments in prepulse inhibition.
Topics: Animals; Dose-Response Relationship, Drug; Glycine; Male; Phencyclidine; Prepulse Inhibition; Rats; Rats, Sprague-Dawley; Receptors, Ghrelin; Receptors, N-Methyl-D-Aspartate; Reflex, Startle; Schizophrenia; Sensory Gating; Signal Transduction; Triazoles | 2015 |
Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study.
Topics: Adolescent; Adult; Antipsychotic Agents; Carbon Radioisotopes; Case-Control Studies; Coffee; Cognition; Humans; Magnetic Resonance Imaging; Male; Neostriatum; Organ Size; Phosphoric Diester Hydrolases; Positron-Emission Tomography; Prefrontal Cortex; Pyridines; Radiopharmaceuticals; Schizophrenia; Schizophrenic Psychology; Smoking; Time Factors; Triazoles; Young Adult | 2017 |
How multiple medication use evolves and the importance of therapeutic trials: the slippery slide.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Asthma; Bronchodilator Agents; Buspirone; Clozapine; Comorbidity; Cooperative Behavior; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Humans; Long-Term Care; Patient Care Team; Piperazines; Referral and Consultation; Schizophrenia; Schizophrenic Psychology; Theophylline; Triazoles | 2008 |
Effect of CFMTI, an allosteric metabotropic glutamate receptor 1 antagonist with antipsychotic activity, on Fos expression in regions of the brain related to schizophrenia.
Topics: Allosteric Regulation; Animals; Antipsychotic Agents; Brain; Isoindoles; Male; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Schizophrenia; Triazoles | 2010 |
A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Animals; Brain; Cognition Disorders; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Female; Glycine Plasma Membrane Transport Proteins; Humans; Inhibitory Concentration 50; Male; Memory Disorders; Mice; Oxadiazoles; Permeability; Rats; Rats, Wistar; Schizophrenia; Triazoles | 2012 |
Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition Disorders; Cyclic Nucleotide Phosphodiesterases, Type 7; Dose-Response Relationship, Drug; Drugs, Investigational; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Male; Memory; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Neural Inhibition; Nootropic Agents; Phosphodiesterase Inhibitors; Quinazolines; Schizophrenia; Spatial Behavior; Triazoles | 2013 |
GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction.
Topics: Animals; Autistic Disorder; Baclofen; Disease Models, Animal; Evoked Potentials, Auditory; Exploratory Behavior; Fluorobenzenes; GABA-B Receptor Agonists; In Situ Hybridization; Intellectual Disability; Interneurons; Male; Mice; Mice, Transgenic; Parvalbumins; Phenotype; Pyramidal Cells; Receptors, N-Methyl-D-Aspartate; Risperidone; Schizophrenia; Social Behavior; Synaptic Potentials; Triazoles | 2012 |
Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: lack of changes after a neonatal bilateral lesion of the ventral hippocampus.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Female; Hippocampus; Male; Pregnancy; Purinergic P1 Receptor Antagonists; Pyrimidines; Raclopride; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Salicylamides; Schizophrenia; Triazoles; Xanthines | 1999 |
Electrophysiological effects of E-5842, a sigma1 receptor ligand and potential atypical antipsychotic, on A9 and A10 dopamine neurons.
Topics: Animals; Antipsychotic Agents; Dopamine; Electrophysiology; Humans; Ligands; Male; Neurons; Pyridines; Rats; Rats, Wistar; Receptors, sigma; Schizophrenia; Sigma-1 Receptor; Triazoles | 1999 |
Fibroblast growth factor-2 is selectively modulated in the rat brain by E-5842, a preferential sigma-1 receptor ligand and putative atypical antipsychotic.
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Dose-Response Relationship, Drug; Fibroblast Growth Factor 2; Male; Neurons; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, sigma; RNA, Messenger; Schizophrenia; Sigma-1 Receptor; Triazoles | 2001 |
Introductory remarks: new agents in psychiatry.
Topics: Antidepressive Agents; Anxiety Disorders; Depression; Humans; Mental Disorders; Piperazines; Pyridines; Schizophrenia; Triazoles; United States; United States Food and Drug Administration | 1973 |